Sargent Bickham Lagudis’s Agios Pharmaceuticals AGIO Stock Holding History

Sargent Bickham Lagudis’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-82	Closed	-$7K	–	746
2018 Q1	$7K	Hold	82	–	–	﹤0.01%	627
2017 Q4	$5K	Hold	82	–	–	﹤0.01%	681
2017 Q3	$5K	Hold	82	–	–	﹤0.01%	688
2017 Q2	$4K	Hold	82	–	–	﹤0.01%	661
2017 Q1	$5K	Hold	82	–	–	﹤0.01%	656
2016 Q4	$3K	Hold	82	–	–	﹤0.01%	647
2016 Q3	$4	Hold	82	–	–	﹤0.01%	653
2016 Q2	$3K	Hold	82	–	–	﹤0.01%	639
2016 Q1	$3K	Buy	+82	New	+$3.51K	﹤0.01%	663

Other funds holding AGIO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Sargent Bickham Lagudis's AGIO Position: Q2 2018 in Review

Sargent Bickham Lagudis sold out of Agios Pharmaceuticals (AGIO) in Q2 2018, closing a stake of 82 shares — an estimated $7K sold.

Sargent Bickham Lagudis first reported a position in AGIO in Q1 2016 and held it in 9 quarters. The position peaked at $7K in Q1 2018. 217 funds tracked by Wall St. Rank hold AGIO as of Q2 2018.

Sargent Bickham Lagudis reported no remaining Agios Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Sargent Bickham Lagudis sold 82 Agios Pharmaceuticals shares in Q2 2018, an estimated $7K.
Sargent Bickham Lagudis first reported a position in Agios Pharmaceuticals in Q1 2016 and held it in 9 quarters.
Sargent Bickham Lagudis's Agios Pharmaceuticals position peaked at $7K in Q1 2018.
217 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2018.

Based on Sargent Bickham Lagudis's 13F filing for Q2 2018, filed 13 Sep 2021.